Work

Dolutegravir once daily with rifampicin for HIV and tuberculosis

Year: 2023

Type: article

Source: The Lancet HIV

DOI: 10.1016/s2352-3018(23)00115-7

Authors: Anushka Naidoo, Kelly E Dooley

Institutions: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Vanderbilt University Medical Center

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institute of Allergy and Infectious Diseases, Fogarty International Center

Awards: Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa, Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa, Mentoring Investigators in HIV and Tuberculosis Therapeutics Research

OpenAlex ID: W4377234094

FWCI: 0.823

Cites: 5

Cited by: 4

Related to: 10